Summary:
Metroplex Clinical Research Center is conducting a phase 2a, randomized, open-label study to evaluate the pharmacodynamics effects and safety of RDEA 3170 administered in combination with Febuxostat compared to Febuxostat administered alone in adult male subjects with gout.
Qualified Participants Must:
• Be between 18 and 75 years of age
•
Have been diagnosed with gout
•
Have not had a major surgery in the last 3 months
•
Have no history of cancer
Qualified Participants May Receive:
Study medication and procedures at no cost and compensation up to $3,725.